about US

Innovative therapies

for neuromuscular

& neurodegenerative

diseases​

The Origins​

Robert Prior: "Being a CMT patient myself, I already knew I wanted to be involved in CMT research when I was only sixteen," says Rob Prior, PhD student in the Ludo Van Den Bosch lab at the VIB-KU Leuven Center for Brain & Disease Research.

Prof. Ludo Van Den Bosch: This lab's pioneering research into Charcot-Marie-Tooth disease (CMT) is what led to the creation of Augustine Therapeutics. From lab to clinic, we're working hard to develop a CMT therapy to help people like Rob and his family!​

At the occasion of the CMT Awareness Month across Europe, you can learn more about Rob's story and the founding of Augustine in this great VIB’s article.

Innovative therapies for neuromuscular and neurodegenerative diseases

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular and neurodegenerative diseases. The newly formed company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB New Venture.​